Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.

Hirsh, Jack; Fuster, Valentı́n

doi:10.1161/01.cir.89.3.1469

Cited by 183 publications

(95 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anticoagulant therapy is the treatment of choice for most patients with DVT. Acute DVT is usually treated with a five-to-seven day course of intravenous unfractionated heparin (UFH) or subcutaneous low molecular weight heparin (LMWH), followed by at least three months of oral anticoagulant therapy [1][2][3]. LMWH have the potential advantage of allowing patients with uncomplicated DVT to be treated at home rather than in the hospital.…”

Section: Introductionmentioning

confidence: 99%

Home treatment of deep venous thrombosis with low molecular weight heparin: Long‐term incidence of recurrent venous thromboembolism

et al. 2001

View full text Add to dashboard Cite

Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH). However, most of the randomized trials comparing a LMWH with UFH described clinical outcomes within 3-6 months. The long-term incidence of recurrent VTE after treatment of DVT with LMWH remains to be established. The primary objective of this retrospective study was to document the long-term incidence of recurrent venous thromboembolism (VTE) in patients with DVT treated with a LMWH, nadroparin in an outpatient basis. The patients were evaluated 46 months after inclusion in two cohorts comparing home treatment with nadroparin (n = 130) with in-hospital treatment with intravenous UFH (n = 149). More than 60% of the patients in the nadroparin group could be treated at home, either entirely or after a short stay in hospital. The age-adjusted thrombosis-free survival was not statistically significant between nadroparin and UFHtreated patients (P = 0.084). There was a nonsignificant trend favoring nadroparin as compared with UFH. The hazard ratio (HR) for recurrent VTE in the nadroparin group with respect to the UFH group was 0.44 (95% confidence interval, 0.17-1.12). No significant differences were observed in overall mortality or major hemorrhage between the two treatment groups. Our study suggests that home treatment of DVT with LMWH is at least as effective and safe as in-hospital UFH after a long-term follow-up period. Am. J. Hematol. 67:10-14, 2001.

show abstract

Section: Introductionmentioning

confidence: 99%

Home treatment of deep venous thrombosis with low molecular weight heparin: Long‐term incidence of recurrent venous thromboembolism

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Ademais, a administração de vitamina K, especialmente por via intravenosa, pode tornar esse paciente refratário à ação do AVK por períodos longos, até de semanas 4 .…”

Section: Discussionunclassified

“…A administração de vitamina K é inadequada na maioria dos casos, pois são necessárias algumas horas até que se elevem os níveis de fatores de coagulação e se restabeleça a hemostasia. Além disto, a administração de vitamina K torna o paciente de risco para tromboembolismo refratário ao tratamento anticoagulante, após a resolução do processo hemorrágico 4 . A administração de PFC reverte mais rapidamente a hipocoagulabilidade nos pacientes com hemorragia cerebral, e deve ser usado em situações de emergência.…”

Section: Discussionunclassified

Tratamento da superdosagem de anticoagulantes orais

Lourenço

Morelli

Vignal

1998

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Purpose - Tratamento da Superdosagem de Anticoagulantes Orais Artigo OriginalOs anticoagulantes orais ou drogas anti-vitamina K (AVK) são administrados para profilaxia de fenômenos tromboembólicos. Sua ação é impedir a carboxilação dos fatores VII, IX, X e II da coagulação, levando à síntese de fatores inativos. Sua ação deve ser monitorizada, de forma cuidadosa e periódica, no sentido de se evitar a superdosagem, que pode levar a sangramento 1 . A monitorização é feita através da medida do tempo de protrombina (TP), expresso pela razão normalizada internacional (RNI), e reflete o efeito anticoagulante do AVK, cuja dose varia para cada indivíduo 2, 3 . Valores de RNI >5 estão associados a risco de sangramento e a reversão do efeito do AVK pode ser conseguido com várias medidas, desde a simples suspensão da droga, a administração de vitamina K ou a administração de plasma fresco congelado (PFC) ou complexo protrombínico, de acordo com a urgência da situação. O objetivo dessa intervenção é levar o valor do RNI, novamente, à faixa

show abstract

“…Anticoagulation is measured by the international normalized ratio (INR) or prothrombin time ratio (PTR). The American Heart Association (AHA) [2] and the American College of Chest Physicians [3] recommend a therapeutic level of anticoagulation of no higher than INR 3.5 or about PTR 2.0 (although other centers [4] have declared no higher than INR 4.0 or about PTR 2.2). A survey in 1996 revealed that 73% of physicians recommended withdrawing warfarin before some or all dental surgeries.…”

Section: Patients On Anticoagulant Drugsmentioning

confidence: 99%

Dentistry and Medical Complexities

et al. 2015

View full text Add to dashboard Cite

Dentistry is a safe profession, even for most medically complex patients. In several cases, fear treating such patients may be based not on scientific specifics but rather on a "mythology" of the dangers of dentistry. The complexities of anticoagulation, artificial joint infections, local anesthetics with or without vasoconstrictors, and endocarditis are discussed. Neither continuous anticoagulation nor antiplatelet medications should be withdrawn for dental surgery. Most artificial joint patients should not receive antibiotic prophylaxis. Local anesthetics and vasoconstrictors can be used safely in most medically complex patients. Although dental treatment is not usually a risk factor for endocarditis, practitioners should consult the updated 2008 American Heart Association statement for recommendations for endocarditis prevention.

show abstract

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.

Cited by 183 publications

References 91 publications

Home treatment of deep venous thrombosis with low molecular weight heparin: Long‐term incidence of recurrent venous thromboembolism

Home treatment of deep venous thrombosis with low molecular weight heparin: Long‐term incidence of recurrent venous thromboembolism

Tratamento da superdosagem de anticoagulantes orais

Dentistry and Medical Complexities

Contact Info

Product

Resources

About